Brolucizumab Injection [Beovu] — Competitive Intelligence Brief

Brolucizumab Injection [Beovu] (Brolucizumab Injection [Beovu]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-VEGF monoclonal antibody fragment. Area: Ophthalmology.

phase 3 Anti-VEGF monoclonal antibody fragment VEGF-A Ophthalmology Small molecule

Target snapshot

Brolucizumab Injection [Beovu] (Brolucizumab Injection [Beovu]) — Yeungnam University College of Medicine. Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brolucizumab Injection [Beovu] TARGET	Brolucizumab Injection [Beovu]	Yeungnam University College of Medicine	phase 3	Anti-VEGF monoclonal antibody fragment	VEGF-A
Lucentis every 4 weeks	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Ziv aflibercept	Ziv aflibercept	Marashi Eye Clinic	marketed	VEGF inhibitor / Antiangiogenic agent	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Anti-VEGF drug	Anti-VEGF drug	Xiaodong Sun	marketed	Anti-VEGF	VEGF-A
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-VEGF monoclonal antibody fragment class)

1. Yeungnam University College of Medicine · 1 drug in this class